Evaluation of Mirus™ for Sedation in Resuscitation (MIRUS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02889055|
Recruitment Status : Recruiting
First Posted : September 5, 2016
Last Update Posted : April 5, 2017
Current recommendations for the conduct of sédationanalgésie ICU encourage the use of the lightest possible sedation strategies, avoiding the administration of benzodiazepines source of longer durations of ventilation and ICU stay of syndrome cessation, mental confusion. Among the proposed alternatives, administration of halogenated volatile agents (sevoflurane) in resuscitation is interesting because their favorable pharmacokinetic even after prolonged administration: no tachyphylaxis, rapid clearance, no withdrawal syndrome.
There are two suitable delivery devices sevoflurane in intensive care, both with CE marking. The device Mirus ™ (Pall Medical, Fribourg, Switzerland) is the newest and it is easy to use and reliable. The objective of this study was to evaluate the use of Mirus ™ device in trauma resuscitation and cardiovascular resuscitation.
Specifically, it will use this modality in case of failure with conventional sedation products (propofol, midazolam): maximum permissible doses, sedation weaning failure due to severe agitation.
|Condition or disease||Intervention/treatment|
|Patient Requiring Mechanical Ventilation||Device: patient requiring the MIRUS (mechanical ventilation)|
|Study Type :||Observational|
|Estimated Enrollment :||70 participants|
|Official Title:||Evaluation of Mirus™ for Sedation in Resuscitation|
|Study Start Date :||September 2015|
|Estimated Primary Completion Date :||October 2017|
|Estimated Study Completion Date :||October 2017|
- ead-time (in minutes) of sevoflurane sedation for obtaining a target RASS score between 1 (anxious) and 2 (mild sedation). [ Time Frame: 24 hours ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02889055
|Contact: Jean-François PAYEN, MD||04 76 76 92 88||JFPayen@cju-grenoble.fr|
|Contact: Stéphane COMBAZ||SCombaz@chu-grenoble.fr|
|University Hospital Grenoble||Recruiting|
|Grenoble, France, 38043|
|Contact: Jean-François PAYEN, MD JFPayen@chu-grenoble.fr|
|Principal Investigator:||Jean-François PAYEN, MD||University Hospital, Grenoble|